Samus Therapeutics, Inc.
A Study of Zelavespib (PU-H71) in Subjects With AP-MPN or BP-MPN
- First Posted Date
- 2022-11-10
- Last Posted Date
- 2022-11-10
- Lead Sponsor
- Samus Therapeutics, Inc.
- Registration Number
- NCT05612633
Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma
- Conditions
- Interventions
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Samus Therapeutics, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT04782609
- Locations
- 🇺🇸
University of California, Las Angeles Medical Center, Los Angeles, California, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Evaluate PU-AD in Subjects With Amyotrophic Lateral Sclerosis
- First Posted Date
- 2020-08-10
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Samus Therapeutics, Inc.
- Registration Number
- NCT04505358
To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia
- Conditions
- Interventions
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Samus Therapeutics, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT04311515
- Locations
- 🇺🇸
JEM Research, Lake Worth, Florida, United States
🇺🇸Advanced Clinical Institute, Inc., Neptune, New Jersey, United States
🇺🇸Brain Matters Research, Delray Beach, Florida, United States
Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib
- Conditions
- Interventions
- First Posted Date
- 2019-05-02
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Samus Therapeutics, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT03935555
- Locations
- 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸Marin Cancer Care - Greenbrae (California Cancer Care A Medical Group, Inc. - Greenbrae), Larkspur, California, United States
🇺🇸MD Anderson, Houston, Texas, United States
A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects
- First Posted Date
- 2019-05-02
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Samus Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03935568
- Locations
- 🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States
Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2017-12-14
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Samus Therapeutics, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT03373877
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Ochsner Clinic Foundation, New Orleans, Louisiana, United States
PET Imaging of Subjects Using 124I-PU-AD
- Conditions
- Interventions
- First Posted Date
- 2017-12-13
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Samus Therapeutics, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT03371420
- Locations
- 🇺🇸
Memorial Sloan Kettering, New York, New York, United States